Enprofylline
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.050.166 |
| Chemical and physical data | |
| Formula | C8H10N4O2 |
| Molar mass | 194.194g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?)(verify) | |
Enprofylline(3-propylxanthine) is axanthinederivative used in the treatment ofasthma,which acts as abronchodilator.It acts primarily as a competitive nonselectivephosphodiesterase inhibitorwith relatively little activity as a nonselectiveadenosine receptorantagonist.[1][2]
References[edit]
- ^Lunell E, Svedmyr N, Andersson KE, Persson CG (1982). "Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease".European Journal of Clinical Pharmacology.22(5): 395–402.doi:10.1007/bf00542541.PMID6288396.S2CID3240010.
- ^Laursen LC (December 1987). "Anti asthmatic effects and pharmacokinetics of enprofylline--a new xanthine derivate".Danish Medical Bulletin.34(6): 289–97.PMID3325233.